133 related articles for article (PubMed ID: 365182)
21. Adjuvant activity of nocardomycoloyl derivatives of N-acetylmuramyldipeptide in mice and guinea pigs.
Saiki I; Uemiya M; Kusama T; Yamamura Y; Azuma I
Microbiol Immunol; 1980; 24(3):265-9. PubMed ID: 6968020
[No Abstract] [Full Text] [Related]
22. Immunoadjuvant activity of synthetic N-acetyl muramyl dipeptide.
Masek K; Zaoral M; Jezek J; Straka R
Experientia; 1978 Oct; 34(10):1363-4. PubMed ID: 738426
[No Abstract] [Full Text] [Related]
23. Stimulation of nonspecific host resistance to infection induced by muramyldipeptides.
Matsumoto K; Ogawa H; Nagase O; Kusama T; Azuma I
Microbiol Immunol; 1981; 25(10):1047-58. PubMed ID: 7031443
[TBL] [Abstract][Full Text] [Related]
24. [Fundamental studies to use the adjuvant activity of 6-o-acylmuramyldipeptides to potentiate cell and humoral immune responses for practical purposes].
Tsujimoto M
J Osaka Univ Dent Sch; 1981 Jun; 26(1):63-83. PubMed ID: 6945426
[No Abstract] [Full Text] [Related]
25. Influence of a synthetic adjuvant (MDP) on qualitative and quantitative changes of serum globulins.
Leclerc C; Audibert F; Chedid L
Immunology; 1978 Dec; 35(6):963-70. PubMed ID: 738768
[TBL] [Abstract][Full Text] [Related]
26. Modulation of the immune response by a synthetic adjuvant and analogs.
Chedid L; Audibert F; Lefrancier P; Choay J; Lederer E
Proc Natl Acad Sci U S A; 1976 Jul; 73(7):2472-5. PubMed ID: 1065901
[TBL] [Abstract][Full Text] [Related]
27. [Adjuvant activity and adjuvant arthritis].
Tanaka A
Kekkaku; 1980 Oct; 55(10):465-7. PubMed ID: 7230587
[No Abstract] [Full Text] [Related]
28. In vivo and in vitro stimulation of nonspecific immunity by the beta-D-p-aminophenyl glycoside of N-acetylmuramyl-L-alanyl-D-isoglutamine and an oligomer prepared by cross-linking with glutaraldehyde.
Parant M; Damais C; Audibert F; Parant F; Chedid L; Sache E; Lefrancier P; Choay J; Lederer E
J Infect Dis; 1978 Sep; 138(3):378-86. PubMed ID: 100563
[TBL] [Abstract][Full Text] [Related]
29. Chemical modification of the C-6 substituent in the carbohydrate moiety of N-acetylmuramoyl-L-alanyl-D-isoglutamine (MDP), and the immunoadjuvant activity.
Okumura H; Tokushima Y; Saiki I; Azuma I; Kiso M; Hasegawa A
Carbohydr Res; 1983 Oct; 122(1):87-98. PubMed ID: 6652634
[TBL] [Abstract][Full Text] [Related]
30. [Inhibition of IgE antibody formation by tubercle bacilli and muramyl peptide].
Kishimoto T
Kekkaku; 1980 Oct; 55(10):467-70. PubMed ID: 6785511
[No Abstract] [Full Text] [Related]
31. Non-specific MIF-like activity induced by the synthetic immunoadjuvant: N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP).
Adam A; Souvannavong V; Lederer E
Biochem Biophys Res Commun; 1978 Nov; 85(2):684-90. PubMed ID: 367370
[No Abstract] [Full Text] [Related]
32. Analysis of the antigenic relationship of various derivatives of n-acetyl-muramyl-l-ala-d-isoglutamine (MDP), using anti-MDP antibodies.
Bahr GM; Carelli C; Audibert F; Modabber F; Chedid L
Mol Immunol; 1982 May; 19(5):737-45. PubMed ID: 7110143
[TBL] [Abstract][Full Text] [Related]
33. [Immunochemistry of tubercle bacilli, with special reference to adjuvant activity (author's transl)].
Azuma I
Kekkaku; 1981 Dec; 56(12):595-607. PubMed ID: 7035731
[No Abstract] [Full Text] [Related]
34. [New technology of vaccine production--international prospect of the development. Development of synthetic immunologic adjuvants and MDP-antigen binding vaccines].
Azuma I
Nihon Rinsho; 1987 Oct; 45(10):2355-61. PubMed ID: 3448269
[No Abstract] [Full Text] [Related]
35. Effects of treatment with muramyl dipeptide and certain of its analogs on resistance to Listeria monocytogenes in mice.
Humphres RC; Henika PR; Ferraresi RW; Krahenbuhl JL
Infect Immun; 1980 Nov; 30(2):462-6. PubMed ID: 7439991
[TBL] [Abstract][Full Text] [Related]
36. Immunoreactive substances of mycobacteria.
Goren MB
Am Rev Respir Dis; 1982 Mar; 125(3 Pt 2):50-69. PubMed ID: 6176156
[No Abstract] [Full Text] [Related]
37. Comparison of muramyl dipeptide, trehalose dimycolate, and dimethyl dioctadecyl ammonium bromide as adjuvants in Brucella abortus 45/20 vaccines.
Woodard LF; Toone NM; McLaughlin CA
Infect Immun; 1980 Nov; 30(2):409-12. PubMed ID: 6777304
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs.
Chedid L; Parant M; Parant F; Lefrancher P; Choay J; Lederer E
Proc Natl Acad Sci U S A; 1977 May; 74(5):2089-93. PubMed ID: 325566
[TBL] [Abstract][Full Text] [Related]
39. The effect of replacement of L-alanine residue by glycine, L-serine or D-alanine in an N-acetylmuramyl-L-alanyl-D-isoglutamine on immunoadjuvancies of molecules.
Kotani S; Watanabe Y; Kinoshita F; Morisaki I; Kato K
Biken J; 1977 Jun; 20(2):39-45. PubMed ID: 588232
[TBL] [Abstract][Full Text] [Related]
40. [A comparative study of the immunological properties of peptidoglycans of different origins].
Zakharova NS; Shepeleva IB; Kalina NG; Britsina MV; Elkina SI; Andronova TM; Ermolova EV
Zh Mikrobiol Epidemiol Immunobiol; 1991 Jan; (1):52-5. PubMed ID: 1858472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
